Suppr超能文献

评估复方米氮平作为慢性肾脏病猫咪的食欲刺激剂。

Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.

机构信息

Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.

Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, USA.

出版信息

J Feline Med Surg. 2020 Apr;22(4):376-383. doi: 10.1177/1098612X19851303. Epub 2019 Jun 4.

Abstract

OBJECTIVES

The aim of this study was to assess the appetite stimulation properties of compounded transdermal mirtazapine (CTM) in cats with chronic kidney disease (CKD).

METHODS

Two sequential double-blind placebo-controlled crossover prospective studies were performed in client-owned cats with stable stage 2 or 3 CKD and a history of decreased appetite. In the first study nine CKD cats were randomized to receive 3.75 mg/0.1 ml CTM gel or placebo on the inner pinna every other day for 3 weeks, then, after a 4 day washout period, the cats were crossed over to the alternate 3 week treatment. In a second study, 10 CKD cats were randomized to receive 1.88 mg/0.1 ml CTM or placebo on the same schedule. Physical examination and serum biochemistry were performed before and after each treatment period, and owners kept daily logs of appetite, activity and eating behaviors. Mirtazapine concentrations in CTM gels and steady-state mirtazapine serum concentrations were measured using liquid chromatography/tandem mass spectrometry.

RESULTS

Administration of both 3.75 mg and 1.88 mg CTM resulted in a statistically significant increase in weight ( = 0.002 for both), increase in appetite ( = 0.01 and = 0.005, respectively), and increase in rate of food consumption ( = 0.03 and = 0.008, respectively). No significant difference in activity or vocalization was seen at either dose; however, individual cats experienced excessive meowing. Median weight increase for the 3.75 mg arm was 0.22 kg (range 0.04-0.44 kg), while median weight increase for the 1.88 mg arm was 0.26 kg (range -0.25 to 0.5 kg). Improvement in body condition score was seen in 5/9 cats in the 3.75 mg arm (P = 0.04) and 6/10 cats in the 1.88 mg arm (P = 0.004).

CONCLUSIONS AND RELEVANCE

CTM increased appetite and resulted in weight gain in CKD cats despite significant inconsistencies in compounding, and may benefit cats in countries where an approved product is not available.

摘要

目的

本研究旨在评估复方透皮米氮平(CTM)对慢性肾脏病(CKD)猫的食欲刺激作用。

方法

在患有稳定期 2 或 3 期 CKD 且有食欲减退史的患宠猫中进行了两项连续的双盲安慰剂对照交叉前瞻性研究。在第一项研究中,将 9 只 CKD 猫随机分为两组,每两天在耳内使用 3.75mg/0.1ml CTM 凝胶或安慰剂,持续 3 周,然后在 4 天洗脱期后交叉至另一个 3 周治疗期。在第二项研究中,将 10 只 CKD 猫随机分为两组,在相同的方案下使用 1.88mg/0.1ml CTM 或安慰剂。在每个治疗期前后进行体格检查和血清生化检查,主人每天记录食欲、活动和进食行为。使用液相色谱/串联质谱法测量 CTM 凝胶中的米氮平浓度和稳态米氮平血清浓度。

结果

使用 3.75mg 和 1.88mg CTM 均导致体重显著增加(均为 = 0.002)、食欲增加(分别为 = 0.01 和 = 0.005)和食物摄入量增加(分别为 = 0.03 和 = 0.008)。在任一剂量下,活动或发声均无明显差异;然而,个别猫出现过度喵喵叫。3.75mg 组的中位体重增加为 0.22kg(范围 0.04-0.44kg),1.88mg 组的中位体重增加为 0.26kg(范围-0.25 至 0.5kg)。在 3.75mg 组的 9 只猫中有 5 只(P = 0.04)和在 1.88mg 组的 10 只猫中有 6 只(P = 0.004)的体况评分得到改善。

结论和相关性

尽管复方制剂存在显著的不一致性,但 CTM 增加了 CKD 猫的食欲并导致体重增加,可能有益于那些没有批准产品的国家的猫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f543/10814656/b828bcaabb83/10.1177_1098612X19851303-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验